Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer
Open Access
- 1 August 2025
- journal article
- research article
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-16
Abstract
Adagrasib, a KRASG12C inhibitor, recently received accelerated approval from the US FDA for the treatment of patients diagnosed with KRASG12C-mutated non-small cell lung cancer. Although adagrasib has demonstrated excellent clinical efficacy and good safety, the molecular mechanism underlying the antitumor activity of adagrasib remains elusive. Here, we report that adagrasib treatment markedly inhibited the growth of cells harboring the KRASG12C mutation, whereas the non-KRASG12C cell lines H1299 and PC-9 were also sensitive to adagrasib, indicating that adagrasib exerted off-target effects. Mechanism studies indicated that adagrasib treatment reduced the level of NRF2 via upregulating its ubiquitination, and NRF2 overexpression can reverse the adagrasib-induced cell death in H23 and H1299 cells. Furthermore, adagrasib treatment significantly increased the cellular ROS level and thereby activating autophagy and AKT signaling pathways in H23 and H1299 cells. Importantly, combination of adagrasib with panobinostat demonstrated enhanced antitumor activity in vitro and in vivo. Overall, our data elucidate a novel mechanism of adagrasib, which will be critical for the clinical application of adagrasib.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LY20H310004)
This publication has 57 references indexed in Scilit:
- Recent histone deacetylase inhibitors in cancer therapyCancer, 2023
- Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS‐mutant human lung cancer cellsMolecular Carcinogenesis, 2023
- Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitorsDrug Discovery Today, 2023
- Knockout of NRF2 triggers prostate cancer cells death through ROS modulation and sensitizes to cisplatinJournal of Cellular Biochemistry, 2022
- Drug library screening identifies histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinomaCancer Medicine, 2022
- AMPK and NRF2: Interactive players in the same team for cellular homeostasis?Free Radical Biology and Medicine, 2022
- GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinomaJournal of Advanced Research, 2022
- Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)Cancer, 2020
- Curcuminoid WZ26, a TrxR1 inhibitor, effectively inhibits colon cancer cell growth and enhances cisplatin-induced cell death through the induction of ROSFree Radical Biology and Medicine, 2019
- Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signalingCancer Letters, 2018